Bone Health & Osteonecrosis After COVID‑19: Causes, Diagnostics, Treatment & Prevention

Corticosteroid use
In severe COVID‑19 with respiratory distress, corticosteroids like dexamethasone or methylprednisolone are often used. These can impair blood flow to bone tissue, leading to cell death (osteonecrosis).
Vascular and thrombotic issues
Micro‑emboli, small clots, and disturbed blood flow during or after COVID‑19 can reduce oxygen/nutrient supply to bone and contribute to osteonecrosis.
Inflammatory responses and immune dysregulation
High inflammation, elevated cytokines, strong immune responses, and disease severity all increase risk of damaging bone microstructure.
Dose and duration
Higher doses, longer steroid courses, earlier onset of symptoms, and more severe illness raise the risk.

Clinical assessment & symptoms
Pain, especially in hip area; limping; movement restriction; worsening with activity.
Screening
For people in risk groups (e.g. those who used steroids), periodic evaluation; MRT is the most reliable for early detection.
Radiological classification
Systems like Ficat, ARCO to define stage, presence of collapse, degree of necrosis.

Stage Treatment Approach

Early (Ficat I–II, no collapse)

Conservative management: rest, avoid weight‑bearing, NSAIDs, Vitamin D & bone support agents; follow‑up MRT.

Intermediate (Ficat II‑III, beginning collapse)

Core decompression; PRP / BMAC therapies; physical therapy & rehabilitation.

Late (Ficat IV, structural collapse, loss of joint function)

Total joint replacement (prosthesis); bone grafting; long recovery and rehab period.

Use corticosteroids only when necessary, at minimal effective dose, shortest duration possible.
Maintain adequate Vitamin D & calcium levels; good nutrition.
Regular safe physical activity.
Periodic imaging (MRT or X‑ray) for those at risk.